Harrow's Acquisition of TYRVAYA: A Game Changer for Dry Eye Treatment
Harrow Pharmaceuticals acquires TYRVAYA, the first FDA-approved nasal spray for dry eye disease, reshaping the market landscape.
Moderna's Historic mRNA Influenza Vaccine Approval: What It Means for Investors
Moderna's mFLUSIVA approval marks a pivotal moment for the company and its investors, showcasing its evolution beyond COVID-19.
Arrowhead Pharmaceuticals: Strategic Move with FDA Priority Review Voucher
Arrowhead Pharmaceuticals secures FDA Priority Review Voucher for plozasiran, aiming to expedite its supplemental NDA filing.
Eli Lilly's Stellar Earnings and Breakthrough Therapy Status: A Game Changer for Investors
Eli Lilly's earnings beat and FDA milestone could redefine its market trajectory.
Arrowhead Pharmaceuticals' Strategic Acquisition: Priority Review Voucher for Plozasiran
Arrowhead's acquisition of a Priority Review Voucher is set to reshape its market strategy and impact its stock.
Eton Pharmaceuticals Expands Portfolio with ASN-001 Acquisition
Eton Pharmaceuticals enhances its pipeline with the acquisition of ASN-001, targeting the infantile hemangioma market.
Johnson & Johnson's Robotic Surgery Breakthrough: A Game Changer for Investors
FDA approval of J&J's OTTAVA system sparks optimism, positioning the company as a strong contender in surgical robotics.
Pfizer's Strategic Shift: Navigating Beyond Covid Revenue
Pfizer's recent Q2 earnings reflect a pivot to non-Covid products as Covid revenue expectations are reduced.
Sunshine Biopharma's New Drug Approval: A Strategic Move into Women's Health
Sunshine Biopharma's approval of a generic drug opens doors to a lucrative women's health market worth $5.2 billion.
Pfizer's Q2 Earnings Beat: A Post-Pandemic Perspective
Pfizer's Q2 earnings exceeded expectations, signaling strong performance from non-COVID products amid adjusted revenue forecasts.
Eli Lilly's FDA Approval: A Catalyst for Market Momentum
Eli Lilly's recent FDA approval sparks momentum in LLY's stock and the broader market, with the Dow rising significantly.
Curium and Lantheus Merger: A Game-Changer for Radiopharmaceuticals
Curium and Lantheus' $8 billion merger could reshape the radiopharmaceutical landscape and offer significant benefits to shareholders.